Nitrofurantoïne Activase (Nitrofurantoin)

Nitrofurantoin is reduced by bacterial enzymes to reactive metabolites that damage bacterial DNA, ribosomal proteins, and carbohydrate‑metabolizing enzymes. This multi‑target attack leads to bactericidal activity that is concentrated in the urine because the drug is rapidly excreted unchanged.

The specific dose and duration are determined by the prescribing clinician based on the patient’s condition, renal function, and local guidelines. Nitrofurantoin dosing is individualized and should follow the prescriber’s instructions.

Nitrofurantoin is classified as pregnancy category B, indicating no evidence of risk in animal studies and limited human data. It may be used during pregnancy when clearly needed, but it is generally avoided near term. Breastfeeding mothers should consult their physician, as small amounts can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then provide pricing, availability, shipping details and any necessary import documentation.

Nitrofurantoin offers targeted urinary tract activity with minimal systemic exposure, making it effective for uncomplicated infections caused by common uropathogens. Compared with broad‑spectrum agents such as trimethoprim‑sulfamethoxazole, it has a lower risk of promoting resistance but may be less suitable for patients with reduced renal function.

Store the tablets at room temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Nitrofurantoïne Activase is taken orally, usually with food or milk to reduce gastrointestinal irritation. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious adverse reactions include pulmonary toxicity (interstitial lung disease or acute respiratory distress), hepatic injury, hemolytic anemia in patients with G6PD deficiency, and severe skin reactions such as Stevens‑Johnson syndrome. Any signs of respiratory difficulty, jaundice, dark urine, or rash require immediate medical evaluation.

Nitrofurantoin is contraindicated in patients with severe renal impairment (creatinine clearance < 30 mL/min), known hypersensitivity to nitrofurantoin, or G6PD deficiency due to the risk of hemolysis. It should also be avoided in late pregnancy (≥ 38 weeks) and in individuals with a history of pulmonary or hepatic reactions to the drug.